A bone-targeting drug-delivery system based on Semaphorin 3A gene therapy ameliorates bone loss in osteoporotic ovariectomized mice
Abstract
No abstract availableKeywords
Funding Information
- National Basic Research Program of China (2016YFC1000505)
- National Natural Science Foundation of China (81120108010, 81570954, 81470727)
This publication has 41 references indexed in Scilit:
- Novel osteoporosis targetsNature Reviews Endocrinology, 2013
- Differing effects of PTH 1–34, PTH 1–84, and zoledronic acid on bone microarchitecture and estimated strength in postmenopausal women with osteoporosis: An 18-month open-labeled observational study using HR-pQCTJournal of Bone and Mineral Research, 2012
- Osteoprotection by semaphorin 3ANature, 2012
- Semaphorins in Angiogenesis and Tumor ProgressionCold Spring Harbor Perspectives in Medicine, 2011
- Osteoporosis: now and the futureThe Lancet, 2011
- New Approaches to the Treatment of OsteoporosisAnnual Review of Medicine, 2011
- Specific Binding and Mineralization of Calcified Surfaces by Small PeptidesCalcified Tissue International, 2009
- Central Control of Bone RemodellingJournal of Neuroendocrinology, 2008
- Osteotropic Peptide That Differentiates Functional Domains of the SkeletonBioconjugate Chemistry, 2007
- Pharmacokinetic and Biodistribution Studies of a Bone-Targeting Drug Delivery System Based onN-(2-Hydroxypropyl)methacrylamide CopolymersMolecular Pharmaceutics, 2006